Abstract

Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards

Author(s): Willis Jordan, Vu Nicole

Issue: Jul/Aug 2026 - Volume 30, Number 4

Page(s): 329-336

Download in electronic PDF format for $75
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 1
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 2
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 3
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 4
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 5
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 6
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 7
  • Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards Page 8

Abstract

Compounded peptides have quickly moved from a niche topic to a growing area of interest among patients and prescribers. These products are promoted for a wide range of uses, including tissue repair, inflammation, metabolic health, and healthy aging. This article examines the proposed uses of these peptides, the concerns raised during the review, and the practical implications for compounders.

Related Keywords

  • Synthetic peptides
  • compounding
  • PCAC
  • FDA
  • BPC-157
  • KPV
  • TB-500
  • MOTS-c
  • Epitalon
  • Semax
  • 503A

Related Categories

  • BUSINESS
  • LEGAL
  • QUALITY CONTROL

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2026
Pg. 329-336
Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards
Author(s): Willis Jordan, Vu Nicole
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Nov/Dec 2020
Pg. 451-458
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Author(s): Allen W Chris, Greeson Nicole MH, Mixon William
Jan/Feb 2018
Pg. 7-16
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
Author(s): Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
May/Jun 2017
Pg. 223-228
Basics of Sterile Compounding: Manipulating Peptides and Proteins
Author(s): Akers Michael J
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Jul/Aug 2020
Pg. 270-276
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
Sep/Oct 2020
Pg. 371-379
Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
May/Jun 2021
Pg. 206-209
FDA-funded Report on Compounded Hormones is Tainted, Analysis Shows
Author(s): Brunner Scott
Jan/Feb 2014
Pg. 6-12
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Author(s): Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
Jul/Aug 2004
Pg. 269-274
Current Topical Treatments in Wound Healing - Part 1
Author(s): Helmke Christopher D
Nov/Dec 2016
Pg. 447-454
Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2
Author(s): Deleruyelle Laura J
Jan/Feb 2016
Pg. 29-36
Performance Improvement in 503A Compounding Pharmacies: A Plan for Assessment, Implementation, and Sustained Success
Author(s): Pritchett Jon, Mixon William, O'Connell Kevin
Sep/Oct 2014
Pg. 379-380
Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A
Author(s): Blankenship Cynthia E
Sep/Oct 2016
Pg. 367-374
Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy
Author(s): Kochanowska-Karamyan Anna J
Mar/Apr 2018
Pg. 92
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Author(s): Allen Loyd V Jr
Mar/Apr 2016
Pg. 99-104
Root Cause Analysis, Part 2: Sterile Compounding
Author(s): Cabaleiro Joe, Jackson Kathleen
May/Jun 2004
Pg. 206-209
Basics of Compounding for Cold Sores or Fever Blisters
Author(s): Allen Loyd V Jr
Nov/Dec 2015
Pg. 453-463
Applying Quality of Design Concepts to Pharmacy Compounding
Author(s): Timko Robert J
Sep/Oct 2018
Pg. 387-398
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Author(s): Ashe Krystina, Baskett Dustin